![Syndax Pharmaceuticals](https://s33007.pcdn.co/wp-content/uploads/2020/05/Syndax.jpg)
Syndax is developing a pipeline of combination therapies in multiple cancer indications. Its lead product candidate, Entinostat, is currently being evaluated in a Phase III clinical trial for advanced HR+ breast cancer. Syndax advanced Entinostat to this pivotal trial based on positive Phase IIb results, meeting endpoints with statistical significance in both PFS and OS.